What New Estrogen Research Tells Us About the Ageing Female Brain
The Daily Capital Briefing — 18 August 2026
One development I’m watching today: new research reopening a question about the relationship between estrogen exposure and brain health in women.
1. New estrogen data reopen an important question about menopause and brain health
A new study published in Neurology examined data from 21,462 women and found that estrogen-only hormone therapy use was associated with lower rates of dementia and less Alzheimer’s-related pathology.
Among women whose brains were examined after death, hormone-therapy use was associated with 35% lower odds of Alzheimer’s pathology after adjustment for factors including age, education, genetics, race and hypertension. It was also associated with 39% lower odds of a clinical dementia diagnosis.
But the findings need substantial qualification.
This was an observational study, so it cannot establish that estrogen prevented dementia. More importantly, women in the study who had used estrogen began treatment at an average age above 70, which is very different from modern menopause practice, where hormone therapy is generally initiated much earlier.
The researchers themselves caution that the findings may therefore not translate directly to women using hormone therapy today. Read More
What I find Interesting
What I find interesting here is how much we still don’t understand about estrogen and the ageing female brain.
Women account for a disproportionate share of Alzheimer’s disease, and menopause represents one of the most significant biological transitions in a woman’s life. Yet the relationship between declining estrogen, hormone therapy and long-term cognitive health remains remarkably difficult to pin down.
This study adds another piece to that puzzle, but it doesn’t resolve it. In fact, the age of the women taking estrogen makes the finding particularly interesting. If estrogen use beginning much later in life is associated with lower Alzheimer’s pathology, what exactly are we observing? Is there a biological effect from estrogen itself? Are there characteristics of women who received estrogen that aren’t fully captured by the analysis? And would we see the same relationship in women starting hormone therapy around menopause today?
Those questions matter because there is a danger of moving too quickly from an association like this to a much more attractive conclusion: that estrogen might protect women against dementia. We simply don’t know that yet.
But I don’t think the appropriate response to uncertainty is to dismiss the finding either. It is to recognise how important the unanswered question is.
We have become much better at thinking about menopause in relation to symptoms, bone health and cardiovascular health. Brain health may ultimately prove to be another important part of that picture, but the science still has some catching up to do.
For me, that is the signal here - a major area of women’s health where the biology is important, the patient population is enormous, and still, some very fundamental questions remain unanswered.